BTIG Initiates Coverage On Jasper Therapeutics with Buy Rating, Announces Price Target of $90
Portfolio Pulse from Benzinga Newsdesk
BTIG has initiated coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and set a price target of $90.
July 08, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG has initiated coverage on Jasper Therapeutics with a Buy rating and a price target of $90, indicating strong confidence in the company's future performance.
The initiation of coverage with a Buy rating and a high price target of $90 by BTIG is a strong positive signal for investors. This suggests that the analyst sees significant upside potential in the stock, which is likely to drive short-term buying interest and upward price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100